TIDMN4P

RNS Number : 7870V

N4 Pharma PLC

10 April 2019

10 April 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

Director/PDMR shareholding

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company ("Ordinary Shares") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share.

As a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital.

Enquiries:

 
 N4 Pharma Plc               Via Alma PR 
  Nigel Theobald, CEO 
 Allenby Capital Limited    Tel: +44(0)203 328 5656 
  James Reeve/Asha Chotai 
 Scott PR                   Tel: +44(0)1477 539 539 
  Georgia Smith

About N4 Pharma plc

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Nigel Theobald 
     ---------------------  ---------------------------------------------- 
 2    Reason for the notification 
     --------------------------------------------------------------------- 
 a)   Position/status        Chief Executive Officer 
     ---------------------  ---------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------- 
 a)   Name                   N4 Pharma PLC 
     ---------------------  ---------------------------------------------- 
 b)   LEI                    213800I841D2RKMFK955 
     ---------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     --------------------------------------------------------------------- 
 a)   Description            Ordinary shares of 0.4p 
       of the financial 
       instrument, 
       type of instrument     GB00BYW8QM32 
       Identification 
       code 
     ---------------------  ---------------------------------------------- 
 b)   Nature of              Purchase of ordinary shares in the Company 
       the transaction 
     ---------------------  ---------------------------------------------- 
 c)   Price(s)                Price(s)   Volume(s) 
       and volume(s)           4.44p      67,343 
                                         ---------- 
     ---------------------  ---------------------------------------------- 
 d)   Aggregated             Aggregated volume: 67,343 
       information            Weighted average price: 4.44 pence per share 
       - Aggregated 
       volume 
       - Price 
     ---------------------  ---------------------------------------------- 
 e)   Date of the            10 April 2019 
       transaction 
     ---------------------  ---------------------------------------------- 
 f)   Place of               London Stock Exchange, XLON 
       the transaction 
     ---------------------  ---------------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Anne-Marie Lawrence 
     ---------------------  ---------------------------------------------- 
 2    Reason for the notification 
     --------------------------------------------------------------------- 
 a)   Position/status        Wife and PCA of Chief Executive Officer 
     ---------------------  ---------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------- 
 a)   Name                   N4 Pharma PLC 
     ---------------------  ---------------------------------------------- 
 b)   LEI                    213800I841D2RKMFK955 
     ---------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     --------------------------------------------------------------------- 
 a)   Description            Ordinary shares of 0.4p 
       of the financial 
       instrument, 
       type of instrument     GB00BYW8QM32 
       Identification 
       code 
     ---------------------  ---------------------------------------------- 
 b)   Nature of              Purchase of ordinary shares in the Company 
       the transaction 
     ---------------------  ---------------------------------------------- 
 c)   Price(s)                Price(s)   Volume(s) 
       and volume(s)           4.44       67,343 
                                         ---------- 
     ---------------------  ---------------------------------------------- 
 d)   Aggregated             Aggregated volume: 67,343 
       information            Weighted average price: 4.44 pence per share 
       - Aggregated 
       volume 
       - Price 
     ---------------------  ---------------------------------------------- 
 e)   Date of the            10 April 2019 
       transaction 
     ---------------------  ---------------------------------------------- 
 f)   Place of               London Stock Exchange, XLON 
       the transaction 
     ---------------------  ----------------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAELEFSENEFF

(END) Dow Jones Newswires

April 10, 2019 06:52 ET (10:52 GMT)

N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas N4 Pharma.
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas N4 Pharma.